Drug Type Small molecule drug |
Synonyms Arlansa, Narlaprevir (USAN/INN) |
Target |
Mechanism NS3/NS4A inhibitors(Hepatitis C virus serine protease, NS3/NS4A inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date RU (03 Jun 2016), |
Regulation- |
Molecular FormulaC36H61N5O7S |
InChIKeyRICZEKWVNZFTNZ-LFGITCQGSA-N |
CAS Registry865466-24-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09644 | Narlaprevir |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hepatitis C | RU | 03 Jun 2016 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic hepatitis C genotype 1 | Phase 1 | - | 01 Jul 2007 | |
Hepatitis C, Chronic | Preclinical | - | 20 Feb 2007 | |
Hepatitis C | Preclinical | US | - |